Medexus Q1 FY2027 adjusted EBITDA rises to USD 4.7 million as GRAFAPEX sales outpace launch spending

Reuters2026/08/10 21:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Medexus posted fiscal Q1 2027 net revenue of USD 28.6 million, up 16.3% year over year, driven by higher GRAFAPEX, IXINITY sales.
Adjusted EBITDA rose 38.2% to USD 4.7 million as GRAFAPEX generated USD 4.9 million net revenue versus USD 3.2 million launch spending.
Operating income increased to USD 2.1 million from USD 0.9 million, reflecting improved operating leverage from GRAFAPEX growth.
Gross margin slipped to 55.6% from 56% due to a prior-year one-time royalty benefit; net income held at USD 544,000.
GRAFAPEX patient demand was USD 4.8 million; 75 transplant centers ordered; fiscal 2027 GRAFAPEX net revenue forecast at USD 30-32 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Medexus Q1 FY2027 adjusted EBITDA rises to USD 4.7 million as GRAFAPEX sales outpace launch spending

You may also like

Crypto prices